| Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer |
2019-09-17 |
| Life Healthcare Group–AC Immune: PET tracer, 201909 collab existent developm Tau PET tracer PI-2620 with Life Molecular Imaging |
2019-09-17 |
| Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners |
2019-09-17 |
| Belyntic–Berlin (govt): investment, 201909 seed financing round totalling €1.3m incl lead investor IBB |
2019-09-16 |
| Belyntic–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €1.3m incl co-investor HTGF |
2019-09-16 |
| Belyntic–PERSON: investment, 201909 seed financing round totalling €1.3m incl co-investor business angel Till Knorr |
2019-09-16 |
| Belyntic–SEVERAL: investment, 201909 seed financing round €1.3m led by IBB + incl HTGF + business angel Till Knorr |
2019-09-16 |
| GenomSys–Club degli Investitori: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Club degli Investitori |
2019-09-16 |
| GenomSys–Dolby Family Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Dolby Family Ventures |
2019-09-16 |
| GenomSys–Elysia Capital: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Elysia Capital |
2019-09-16 |
| GenomSys–Preon Capital: investment, 201909 financing round Series A totalling CHF9.3m incl lead investor Preon Capital |
2019-09-16 |
| GenomSys–Pygar: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Pygar family office |
2019-09-16 |
| GenomSys–SEVERAL: investment, 201909 financing round Series A CHF9.3m led by Preon Capital |
2019-09-16 |
| GenomSys–Susman Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Susman Ventures |
2019-09-16 |
| OTHER–Curetis: molecular diagnostics, 201909– collab r+d + option for NGS-based antibiotic resistance testing of Ares Genetics with global IVD firm |
2019-09-16 |
| Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures |
2019-09-12 |
| Khanu Management–Austria (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl aws |
2019-09-12 |
| Khanu Management–EU (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl European Investment Fund |
2019-09-12 |
| Khanu Management–Max Planck: investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl Max Planck Foundation |
2019-09-12 |
| Khanu Management–SEVERAL: investment, 201909 1st closing €60m of KHAN Technology Transfer Fund I |
2019-09-12 |
| Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule r+d to Orion Pharma |
2019-09-11 |
| Bayer–Minapharm: GlymaxX technology, 201909– license for use in cell line developm for cancer antibody candidate of Bayer |
2019-09-10 |
| Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America |
2019-09-10 |
| BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market |
2019-09-09 |
| ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 |
2019-09-06 |
| iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv |
2019-09-05 |
| PathoQuest–SEVERAL: investment, 201909 financing round €7.57m incl venture loan from Norgine Ventures |
2019-09-05 |
| Roche–Abionic: in vitro diagnostics, 201909– collab developm + supply abioSCOPE IVD PoC asthma test panel for asthma management in US for Genentech |
2019-09-05 |
| BioNTech–Gates Foundation: investment, 201909 equity investment $55m in connection with anti-infectives collaboration |
2019-09-04 |
| Boehringer–Lupin: MEK inhibitor, 201909– license $20m upfront + $700m milestones + royalties to LNP3794 for combi with KRAS inhibitors for cancer |
2019-09-04 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| Gates Foundation–BioNTech: anti-infectives, 201909– collab developm of HIV + TB immunotherapies with up to $100m funding incl equity investment $55m |
2019-09-04 |
| FU Berlin–Agilent: mass spectrometer, 201909 supply existent LC/MS/MS + GC/MS systems at FU Berlin used in doping control study with Agilent support |
2019-09-03 |
| Grünenthal–Univ Queensland: pain drugs, 201909– collab develop therapies derived from group of alpha-conotoxins for chronic neuropathic pain |
2019-09-03 |
| Univ College London–Bruker: atomic force microscope, 201908 supply existent London Centre for Nanotechnology long-term user of NanoWizard systems |
2019-09-02 |
| Biocrates–MIG Founds: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure |
2019-09-01 |
| Biocrates–SEVERAL: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure |
2019-09-01 |
| Biocrates–Xolaris Service KVG: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure |
2019-09-01 |
| Celgene–Immatics: cell therapy, 201908– strategic collab + excl option $75m upfront + $1.5b milestones + royalties for three TCR-T targets |
2019-08-28 |
| Spitality–Berlin (govt): investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin |
2019-08-27 |
| Spitality–Capacura: investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin |
2019-08-27 |
| Spitality–SEVERAL: investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin to advance Krankenhaus.de |
2019-08-27 |
| ADC Therapeutics–Freenome: pharmacodiagnostics, 201908– collab developm multiomics biomarker for ADCT-402 treatment in DLBCL |
2019-08-26 |
| Univ Florence–Bruker: NMR spectrometer, 201908– supply expected first customer for new 1.2 GHz NMR spectrometer |
2019-08-26 |
| Merck (US)–Themis Bioscience: vaccine technology, 201908– collab research + license for use of MV technology platform for vaccine development |
2019-08-22 |
| Themis Bioscience–Merck (US): investment, 201908 equity investment €na by MSD as part of vaccine collaboration |
2019-08-22 |
| Oncorus–SEVERAL: investment, 201908 financing round Series B $79.5m co-led by Cowen Healthcare Investments + Perceptive Advisors |
2019-08-21 |
| Araris Biotech–Redalpine: investment, 201908 seed financing round totalling CHF2.5m incl investor Redalpine |
2019-08-20 |
| Araris Biotech–Schroders: investment, 201908 seed financing round totalling CHF2.5m incl investor Schroder Adveq |
2019-08-20 |
| Araris Biotech–SEVERAL: investment, 201908 seed financing round CHF2.5m with Redalpine + Schroder Adveq + VI Partners |
2019-08-20 |
| Araris Biotech–VI Partners: investment, 201908 seed financing round totalling CHF2.5m incl investor VI Partners |
2019-08-20 |
| Bayer–Elanco: investment, 201908– acquisition of Bayer Animal Health business for $5.3b in cash + $2.3b in shares |
2019-08-20 |
| Boehringer–Univ Texas: cancer drugs, 201908– collab new virtual r+d center to advance new cancer therapies incl KRAS inhibitors + TRAILR2 agonists |
2019-08-12 |
| Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options |
2019-08-12 |
| LemnaTec–Nynomic: investment, 201908 acquisition €na of assets of bankrupt LemnaTec Gmbh by Nynomic AG |
2019-08-12 |
| Biognosys–SEVERAL: investment, 201908 financing round Series G from existing + new institutional + private investors |
2019-08-08 |
| BlueRock Therapeutics–Bayer: investment, 201808– acquisition 100% by acquiring remaining 59.2% for $240m upfront + $360m milestones |
2019-08-08 |
| a:head bio–red-stars.com data: investment, 201908– milestone-dependent 7-digit EUR seed investment by red-stars.com data AG in a:head bio AG |
2019-08-07 |
| BSSN Software–Merck (DE): investment, 201908 acquisition €na of BSSN Software GmbH by Merck KGaA |
2019-08-06 |
| Fosanis–Ananda Ventures: investment, 201908 milllion Euro financing round from Ananda Impact Ventures + VC Fonds Technologie Berlin |
2019-08-06 |
| Fosanis–Berlin (govt): investment, 201908 milllion Euro financing round from Ananda Impact Ventures + VC Fonds Technologie Berlin |
2019-08-06 |
| Fosanis–SEVERAL: investment, 201908 milllion Euro financing round from Ananda Impact Ventures + VC Fonds Technologie Berlin to advance mika app |
2019-08-06 |
| Merck (DE)–BSSN Software: laboratory software, 2014– supply Merck working with BSSN Software |
2019-08-06 |
| Platomics–SEVERAL: investment, 201908 investment €7-digit from undisclosed investors |
2019-08-06 |
| Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB |
2019-08-05 |
| GNA Biosolutions–Bavaria (govt): investment, 201908 financing round Series C totalling $13.5m incl new investor Wachstumsfonds Bayern |
2019-08-05 |
| GNA Biosolutions–Bosch: investment, 201908 financing round Series C totalling $13.5m incl existing investor Robert Bosch Venture Capital |
2019-08-05 |
| GNA Biosolutions–btov Partners: investment, 201908 financing round Series C totalling $13.5m incl existing investor btov Partners |
2019-08-05 |
| GNA Biosolutions–Germany (govt): investment, 201908 financing round Series C totalling $13.5m incl existing investor KfW |
2019-08-05 |
| GNA Biosolutions–GreyBird Ventures: investment, 201908 financing round Series C totalling $13.5m incl new investor GreyBird Ventures |
2019-08-05 |
| GNA Biosolutions–Mey Capital Matrix: investment, 201908 financing round Series C totalling $13.5m incl existing investor Mey Capital Matrix |
2019-08-05 |
| GNA Biosolutions–Occident Group: investment, 201908 financing round Series C totalling $13.5m incl new investor Occident |
2019-08-05 |
| GNA Biosolutions–SEVERAL: investment, 201908 financing round Series C $13.5m from new + existing EU + US investors |
2019-08-05 |
| GNA Biosolutions–SHS: investment, 201908 financing round Series C totalling $13.5m incl existing investor SHS Gesellschaft für Beteiligungsmanagement |
2019-08-05 |
| GNA Biosolutions–UVC Partners: investment, 201908 financing round Series C totalling $13.5m incl existing investor UVC Partners |
2019-08-05 |
| Inveox–SEVERAL: investment, 201908 3rd financing round €17m |
2019-08-05 |
| Babylon Health–SEVERAL: investment, 201908 financing round $550m from existing + new investors |
2019-08-02 |
| Immunic–Germany (govt): grant, 201908–202207 BMBF grant €654k to support German-Japanese research project with InnoMuNIiCH project |
2019-08-01 |
| Wellington Partners–Consilium: public relations, 201907 service existent by CSC |
2019-07-31 |
| Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF |
2019-07-31 |
| Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital |
2019-07-31 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx |
2019-07-31 |
| Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company |
2019-07-31 |
| Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO |
2019-07-31 |
| Quanta Dialysis Technologies–SEVERAL: investment, 201907 financing round Series C £38m led by Swiss family office + btov Partners |
2019-07-29 |
| 908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al |
2019-07-25 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| Merck (DE)–908 Devices: biopharma production technology, 201907– collab 908 + MilliporeSigma + Univ North Carolina on bioreactor process analytics |
2019-07-25 |
| EverlyWell–PerkinElmer: consumer diagnostics, 201907– collab + supply CAP lab services immunoassays + genomic tests for US home health test market |
2019-07-24 |
| Freenome–Roche: investment, 201907 financing round Series B totalling $160m incl new + co-investor Roche Venture Fund |
2019-07-24 |
| Freenome–SEVERAL: investment, 201907 financing round Series B $160m co-led by RA Capital Management + Polaris Partners + incl Roche Venture Fund |
2019-07-24 |
| Gilead–Novartis: virostatic agents, 201907– license excl ww for three preclinical antivirals incl upfront payment plus $291m milestones + royalties |
2019-07-19 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Boehringer–Bridge Biotherapeutics: autotaxin inhibitor, 201907– collab + ww license BBT-877 up to €45m upfront/near-term + up to €1.1b + royalties |
2019-07-18 |
| MIT–Merck (DE): CRISPR technology, 201907– collab pooling of IP from Merck + Broad Institute for licensing CRISPR for r+d by Broad |
2019-07-18 |
| Pyxis Oncology–Agent Capital: investment, 201907 financing round Series A totalling $22m incl co-investor Agent Capital |
2019-07-17 |
| Pyxis Oncology–Bayer: investment, 201907 financing round Series A totalling $22m incl lead investor Leaps by Bayer |
2019-07-17 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 8 9 10 ... 30 31 32 
Date![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
